NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

T. A. Yap; N. Ngoi; E. E. Dumbrava; D. D. Karp; J. Rodon Ahnert; S. Fu; D. S. Hong; A. Naing; S. Pant; S. A. Piha-Paul; V. Subbiah; A. M. Tsimberidou; D. Dufner; J. Rhudy; S. Gore; S. P. Ivy; Y. Yuan; S. N. Westin; G. B. Mills; F. Meric-Bernstam

doi:10.1016/S0959-8049(22)00822-X

NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

T. A. Yap, N. Ngoi, E. E. Dumbrava, D. D. Karp, J. Rodon Ahnert, S. Fu, D. S. Hong, A. Naing, S. Pant, S. A. Piha-Paul, V. Subbiah, A. M. Tsimberidou, D. Dufner, J. Rhudy, S. Gore, S. P. Ivy, Y. Yuan, S. N. Westin, G. B. Mills, F. Meric-Bernstam

Cell Developmental and Cancer Biology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	S7
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00822-X
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)00822-X

Cite this

Yap, T. A., Ngoi, N., Dumbrava, E. E., Karp, D. D., Rodon Ahnert, J., Fu, S., Hong, D. S., Naing, A., Pant, S., Piha-Paul, S. A., Subbiah, V., Tsimberidou, A. M., Dufner, D., Rhudy, J., Gore, S., Ivy, S. P., Yuan, Y., Westin, S. N., Mills, G. B., & Meric-Bernstam, F. (2022). NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. European Journal of Cancer, 174, S7. https://doi.org/10.1016/S0959-8049(22)00822-X

NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. / Yap, T. A.; Ngoi, N.; Dumbrava, E. E. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S7.

Research output: Contribution to journal › Article › peer-review

Yap, TA, Ngoi, N, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, S, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB & Meric-Bernstam, F 2022, 'NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers', European Journal of Cancer, vol. 174, pp. S7. https://doi.org/10.1016/S0959-8049(22)00822-X

Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S et al. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. European Journal of Cancer. 2022 Oct;174:S7. doi: 10.1016/S0959-8049(22)00822-X

Yap, T. A. ; Ngoi, N. ; Dumbrava, E. E. et al. / NCI10329 : Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. In: European Journal of Cancer. 2022 ; Vol. 174. pp. S7.

@article{7be2120cf7dc4a699b97f40aca248041,

title = "NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers",

author = "Yap, {T. A.} and N. Ngoi and Dumbrava, {E. E.} and Karp, {D. D.} and {Rodon Ahnert}, J. and S. Fu and Hong, {D. S.} and A. Naing and S. Pant and Piha-Paul, {S. A.} and V. Subbiah and Tsimberidou, {A. M.} and D. Dufner and J. Rhudy and S. Gore and Ivy, {S. P.} and Y. Yuan and Westin, {S. N.} and Mills, {G. B.} and F. Meric-Bernstam",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00822-X",

language = "English (US)",

volume = "174",

pages = "S7",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - NCI10329

T2 - Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers

AU - Yap, T. A.

AU - Ngoi, N.

AU - Dumbrava, E. E.

AU - Karp, D. D.

AU - Rodon Ahnert, J.

AU - Fu, S.

AU - Hong, D. S.

AU - Naing, A.

AU - Pant, S.

AU - Piha-Paul, S. A.

AU - Subbiah, V.

AU - Tsimberidou, A. M.

AU - Dufner, D.

AU - Rhudy, J.

AU - Gore, S.

AU - Ivy, S. P.

AU - Yuan, Y.

AU - Westin, S. N.

AU - Mills, G. B.

AU - Meric-Bernstam, F.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140441238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140441238&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00822-X

DO - 10.1016/S0959-8049(22)00822-X

M3 - Article

AN - SCOPUS:85140441238

SN - 0959-8049

VL - 174

SP - S7

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this